340B Report Conclusions Valid Despite Underlying Data Problems, IG Says
This article was originally published in The Pink Sheet Daily
Executive Summary
HHS Office of Inspector General withdraws its report on 340B drug pricing because of incorrect data mistakenly supplied by CMS. OIG plans to conduct a wider review of the 340B program before reissuing the report.